Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) posted its earnings results on Friday. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02), Zacks reports. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo updated its FY 2026 guidance to 0.870-0.870 EPS.
Daiichi Sankyo Price Performance
OTCMKTS:DSNKY traded down $2.09 during trading hours on Friday, reaching $16.14. 92,402 shares of the company’s stock were exchanged, compared to its average volume of 391,373. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $30.07 billion, a P/E ratio of 17.17, a price-to-earnings-growth ratio of 3.10 and a beta of -0.17. Daiichi Sankyo has a 12 month low of $14.98 and a 12 month high of $27.50. The business’s 50-day simple moving average is $16.52 and its two-hundred day simple moving average is $17.74.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the company. Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Daiichi Sankyo has a consensus rating of “Hold”.
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.
Featured Stories
- Five stocks we like better than Daiichi Sankyo
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
